Ishihara Akane, Kanatani Akio, Mashiko Satoshi, Tanaka Takeshi, Hidaka Masayasu, Gomori Akira, Iwaasa Hisashi, Murai Naomi, Egashira Shin-ichiro, Murai Takashi, Mitobe Yuko, Matsushita Hiroko, Okamoto Osamu, Sato Nagaaki, Jitsuoka Makoto, Fukuroda Takahiro, Ohe Tomoyuki, Guan Xiaoming, MacNeil Douglas J, Van der Ploeg Lex H T, Nishikibe Masaru, Ishii Yasuyuki, Ihara Masaki, Fukami Takehiro
Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd., 3 Okubo, Tsukuba 300-2611, Japan.
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7154-8. doi: 10.1073/pnas.0510320103. Epub 2006 Apr 24.
Neuropeptide Y (NPY) is thought to have a major role in the physiological control of energy homeostasis. Among five NPY receptors described, the NPY Y5 receptor (Y5R) is a prime candidate to mediate some of the effects of NPY on energy homeostasis, although its role in physiologically relevant rodent obesity models remains poorly defined. We examined the effect of a potent and highly selective Y5R antagonist in rodent obesity and dietary models. The Y5R antagonist selectively ameliorated diet-induced obesity (DIO) in rodents by suppressing body weight gain and adiposity while improving the DIO-associated hyperinsulinemia. The compound did not affect the body weight of lean mice fed a regular diet or genetically obese leptin receptor-deficient mice or rats, despite similarly high brain Y5R receptor occupancy. The Y5R antagonist acts in a mechanism-based manner, as the compound did not affect DIO of Y5R-deficient mice. These results indicate that Y5R is involved in the regulation and development of DIO and suggest utility for Y5R antagonists in the treatment of obesity.
神经肽Y(NPY)被认为在能量平衡的生理控制中起主要作用。在已描述的五种NPY受体中,NPY Y5受体(Y5R)是介导NPY对能量平衡某些作用的主要候选者,尽管其在生理相关的啮齿动物肥胖模型中的作用仍不清楚。我们研究了一种强效且高度选择性的Y5R拮抗剂在啮齿动物肥胖和饮食模型中的作用。Y5R拮抗剂通过抑制体重增加和肥胖,同时改善与饮食诱导肥胖(DIO)相关的高胰岛素血症,选择性地改善了啮齿动物的饮食诱导肥胖。尽管脑Y5R受体占有率同样很高,但该化合物对喂食常规饮食的瘦小鼠或基因肥胖的瘦素受体缺陷小鼠或大鼠的体重没有影响。Y5R拮抗剂以基于机制的方式起作用,因为该化合物对Y5R缺陷小鼠的DIO没有影响。这些结果表明Y5R参与了DIO的调节和发展,并提示Y5R拮抗剂在肥胖治疗中的应用价值。